JP2015530971A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530971A5
JP2015530971A5 JP2015520685A JP2015520685A JP2015530971A5 JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5 JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5
Authority
JP
Japan
Prior art keywords
seq
tau
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520685A
Other languages
English (en)
Japanese (ja)
Other versions
JP6345655B2 (ja
JP2015530971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049333 external-priority patent/WO2014008404A1/en
Publication of JP2015530971A publication Critical patent/JP2015530971A/ja
Publication of JP2015530971A5 publication Critical patent/JP2015530971A5/ja
Application granted granted Critical
Publication of JP6345655B2 publication Critical patent/JP6345655B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520685A 2012-07-03 2013-07-03 タウに対する抗体 Expired - Fee Related JP6345655B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30
PCT/US2013/049333 WO2014008404A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098889A Division JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体

Publications (3)

Publication Number Publication Date
JP2015530971A JP2015530971A (ja) 2015-10-29
JP2015530971A5 true JP2015530971A5 (enExample) 2016-08-18
JP6345655B2 JP6345655B2 (ja) 2018-06-20

Family

ID=49882495

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015520685A Expired - Fee Related JP6345655B2 (ja) 2012-07-03 2013-07-03 タウに対する抗体
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Country Status (17)

Country Link
US (2) US9834596B2 (enExample)
EP (2) EP2870176A4 (enExample)
JP (3) JP6345655B2 (enExample)
KR (3) KR20200013072A (enExample)
CN (2) CN108623682A (enExample)
AU (3) AU2013286680B2 (enExample)
BR (1) BR112014033116B1 (enExample)
CA (1) CA2877397A1 (enExample)
HK (1) HK1209768A1 (enExample)
IL (3) IL236409B (enExample)
IN (1) IN2015KN00007A (enExample)
MX (2) MX359555B (enExample)
MY (1) MY171473A (enExample)
NZ (2) NZ703423A (enExample)
RU (2) RU2668159C2 (enExample)
SG (3) SG10201708959WA (enExample)
WO (1) WO2014008404A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CA2952745A1 (en) * 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
CA2991451A1 (en) * 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
FI3334761T3 (fi) * 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
CN105158483A (zh) * 2015-09-16 2015-12-16 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
RU2760875C1 (ru) 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
AU2017359944B2 (en) 2016-11-15 2024-07-18 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
ES3008133T3 (en) 2016-12-16 2025-03-21 H Lundbeck As Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
KR20190134997A (ko) * 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
CA3055957A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
TWI750419B (zh) * 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CA3094934A1 (en) 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
US11629175B2 (en) 2018-04-27 2023-04-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for preparing PHFS-like Tau aggregates
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
IL286359B2 (en) * 2019-03-18 2024-06-01 Regeneron Pharma Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
KR20240126075A (ko) * 2019-03-18 2024-08-20 리제너론 파마슈티칼스 인코포레이티드 타우 시딩 또는 응집의 유전적 변형제를 식별하기 위한 CRISPR/Cas 스크리닝 플랫폼
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
CN114430744B (zh) * 2019-07-15 2024-06-21 阿德尔公司 抗Tau抗体及其用途
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
CA3156678A1 (en) 2019-10-09 2021-04-15 Bluerock Therapeutics Lp Cells with sustained transgene expression
JP2023504699A (ja) * 2019-12-04 2023-02-06 エイシー イミューン ソシエテ アノニム 治療および診断のための新規な分子
EP4241088A1 (en) * 2020-11-09 2023-09-13 Meso Scale Technologies, LLC Methods and kits for detecting tau
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
MX2023011340A (es) 2021-03-26 2023-12-14 Janssen Biotech Inc Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
BR112023019546A2 (pt) 2021-03-26 2023-10-31 Janssen Biotech Inc Anticorpos anti-tau e usos dos mesmos
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
IL318722A (en) * 2022-08-23 2025-03-01 Washington University St Louis Anti-tau MTBR antibodies and methods for detecting cleaved tau fragments and uses thereof
WO2025018933A1 (en) * 2023-07-20 2025-01-23 Montoliu Gaya Laia P-tau immunoassay

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO884368L (no) 1987-10-02 1989-04-03 Du Pont Immunanalyse ved anvendelse av igg-innfangelsesantistoff og multippel, monoklonalt antistoffpaavisningssystem.
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
WO1993008302A1 (en) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AU710952B2 (en) 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
EP1112500B1 (en) 1998-09-08 2004-09-22 Innogenetics N.V. Tau as a marker for early cns damage
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003057881A1 (en) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI438010B (zh) 2002-05-02 2014-05-21 Wyeth Corp 卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物
JP4414332B2 (ja) 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
AU2005327652A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
HRP20140783T1 (hr) 2008-04-24 2014-09-12 Bristol-Myers Squibb Company Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
EP2365802B1 (en) * 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
MX2012001194A (es) * 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
HUE040281T2 (hu) * 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantitest markerek traumás agysérülés diagnózisára
BR112012008381A2 (pt) 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) interação fkbp52-tau como novo alvo terapêutico para tratar os distúrbios neurológicos envolvendo disfunção da tau
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
DK2625198T3 (en) 2010-10-07 2015-09-28 Ac Immune Sa Antibodies that recognize the phosphorylated tau
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
SMT201800109T1 (it) 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
BR112014015323B1 (pt) 2011-12-20 2022-09-27 Janssen Biotech, Inc Anticorpos anti-phf-tau, seu método de produção, polinucleotídeo isolado que codifica uma vh de anticorpo, e vetor
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
SI2857039T1 (sl) 2012-05-31 2020-03-31 Osaka City University Terapevtsko sredstvo ali profilaktično sredstvo za demenco
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
AU2013305848B2 (en) 2012-08-21 2020-10-15 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
WO2014059442A2 (en) 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Similar Documents

Publication Publication Date Title
JP2015530971A5 (enExample)
RU2015103228A (ru) Антитела против тау
JP2014526898A5 (enExample)
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2013500940A5 (enExample)
JP2010526028A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2013538057A5 (enExample)
JP2017535257A5 (enExample)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
JP2015535828A5 (enExample)
JP2013500941A5 (enExample)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2021500916A5 (enExample)
JP2014511179A5 (enExample)
JP2016508496A5 (enExample)
JP2013506428A5 (enExample)
HRP20230844T1 (hr) Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
JP2013198490A5 (enExample)
JP2014512809A5 (enExample)
JP2015531768A5 (enExample)
JP2016501881A (ja) 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質